In contrast, the prolonged in vitro treatment of ovarian cancer cells with thymoquinone did not result in NFκB activation, suggesting that there are specific factors within the TME which support the activation of NFκB in TAMs, in vivo [50]. The gene discussed is NFKB1; the disease is ovarian carcinoma.